Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

A Variant in RUNX3 Is Associated with the Risk of Ankylosing Spondylitis in Koreans

  • Cho, Sung-Min (Department of Microbiology, College of Medicine, The Catholic University of Korea) ;
  • Jung, Seung-Hyun (Integrated Research Center for Genome Polymorphism, College of Medicine, The Catholic University of Korea) ;
  • Chung, Yeun-Jun (Department of Microbiology, College of Medicine, The Catholic University of Korea)
  • Received : 2017.04.28
  • Accepted : 2017.05.09
  • Published : 2017.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Ankylosing spondylitis (AS) is a chronic autoinflammatory disease that affects the spine and sacroiliac joints. Regarding its etiology, although HLA-B27 is known to be the strongest genetic factor of AS, much evidence suggests the potential contribution of non-MHC genes to the susceptibility to AS. Most of these non-MHC genes have been discovered in non-Asian populations; however, just some of them have been validated in Koreans. In this study, we aimed to identify additional AS-associated single-nucleotide polymorphism (SNP) candidates by replicating the candidate SNPs in Korean AS patients and healthy controls. For this, we selected three SNPs (rs11249215 in RUNX3, rs6556416 in IL12B, and rs8070463 in TBKBP1), which were previously reported as risk factors of AS but have not been studied in Koreans, and performed genotyping assays using a total of 1138 Korean samples (572 AS patients and 566 healthy controls). Of the three SNP candidates, one SNP in RUNX3 (rs11249215) was significantly associated with the risk of AS (odds ratio, 1.31; 95% confidence interval, 1.02 to 1.68, p = 0.03). These results will be helpful in elucidating the pathogenesis of AS and may be useful for developing AS risk prediction models in Koreans.

Keywords

References

  1. van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984;27:241-249. https://doi.org/10.1002/art.1780270301
  2. Brophy S, Hickey S, Menon A, Taylor G, Bradbury L, Hamersma J, et al. Concordance of disease severity among family members with ankylosing spondylitis? J Rheumatol 2004;31:1775-1778.
  3. Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC); Burton PR, Clayton DG, Cardon LR, Craddock N, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-1337. https://doi.org/10.1038/ng.2007.17
  4. Evans DM, Spencer CC, Pointon JJ, Su Z, Harvey D, Kochan G, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011;43:761-767. https://doi.org/10.1038/ng.873
  5. Lin Z, Bei JX, Shen M, Li Q, Liao Z, Zhang Y, et al. A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet 2011;44:73-77.
  6. Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 2010;42:123-127. https://doi.org/10.1038/ng.513
  7. Jung SH, Yim SH, Hu HJ, Lee KH, Lee JH, Sheen DH, et al. Genome-wide copy number variation analysis identifies deletion variants associated with ankylosing spondylitis. Arthritis Rheumatol 2014;66:2103-2112. https://doi.org/10.1002/art.38650
  8. Haroon N, Inman RD, Learch TJ, Weisman MH, Lee M, Rahbar MH, et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013;65:2645-2654.
  9. Sieper J, Rudwaleit M. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis 2005;64 Suppl 4:iv61-iv64.
  10. Wallis D, Inman RD. Recognition of preclinical and early disease in axial spondyloarthritis. Rheum Dis Clin North Am 2014;40:685-697. https://doi.org/10.1016/j.rdc.2014.07.011
  11. Jung SH, Cho SM, Yim SH, Kim SH, Park HC, Cho ML, et al. Developing a risk-scoring model for ankylosing spondylitis based on a combination of HLA-B27, single-nucleotide polymorphism, and copy number variant markers. J Rheumatol 2016;43:2136-2141. https://doi.org/10.3899/jrheum.160347
  12. Lian Z, Chai W, Shi LL, Chen C, Liu J, Wang Y. Analysis of PPARGC1B, RUNX3 and TBKBP1 polymorphisms in Chinese Han patients with ankylosing spondylitis: a case-control study. PLoS One 2013;8:e61527. https://doi.org/10.1371/journal.pone.0061527
  13. Zhang L, Fan D, Liu L, Yang T, Ding N, Hu Y, et al. Association study of IL-12B polymorphisms susceptibility with ankylosing spondylitis in mainland Han population. PLoS One 2015;10:e0130982. https://doi.org/10.1371/journal.pone.0130982
  14. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368. https://doi.org/10.1002/art.1780270401
  15. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575. https://doi.org/10.1086/519795
  16. Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, et al. Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci U S A 2003;100:7731-7736. https://doi.org/10.1073/pnas.1232420100
  17. Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D, et al. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J 2004;23:969-979. https://doi.org/10.1038/sj.emboj.7600085
  18. Apel M, Uebe S, Bowes J, Giardina E, Korendowych E, Juneblad K, et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis, exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum 2013;65:1224-1231. https://doi.org/10.1002/art.37885
  19. Wang W, Ma Y, Xu Y, Sheng Y, Gao J, Zuo X, et al. RUNX3 gene polymorphisms are associated with clinical features of systemic lupus erythematosus in Chinese Han population. J Dermatol Sci 2015;80:69-71. https://doi.org/10.1016/j.jdermsci.2015.07.005
  20. Vecellio M, Roberts AR, Cohen CJ, Cortes A, Knight JC, Bowness P, et al. The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression. Ann Rheum Dis 2016;75:1534-1540. https://doi.org/10.1136/annrheumdis-2015-207490

Cited by

  1. The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science vol.9, pp.1664-3224, 2018, https://doi.org/10.3389/fimmu.2018.02668
  2. ERAP1/ERAP2 and RUNX3 polymorphisms are not associated with ankylosing spondylitis susceptibility in Chinese Han vol.193, pp.1, 2018, https://doi.org/10.1111/cei.13121